ALLOPREGNANOLONA INDUCE LA PROLIFERACIÓN Y MIGRACIÓN DE LAS LÍNEAS CELULARES DE CARCINOMA OVÁRICO HUMANO IGROV-1 Y SKOV-3.

SANHUEZA, MARIA DE LOS ANGELES; RODRIGUEZ, C.E; PELEGRINA, LAURA T; CACERES, ANTONELLA; LACONI M. R

Mendoza

Congreso; XXXIV Reunion cientifica Anual de la Sociedad de Biología de Cuyo; 2016

Sociedad de Biología de cuyo

A207ALLOPREGNANOLONE INDUCES PROLIFERATION AND MIGRATION OF HUMAN OVARIAN CELL LINE IGROV-1 AND SKOV-3Sanhueza MA*, Pelegrina LT*, Cáceres ARR, Rodriguez CE, Laconi MR.(*)Equal collaboration.Laboratorio de Fisio-patología ovárica. INBIOMED-IMBECU-CONICET, Mendoza, Argentina.Ovarian carcinoma is one of the most common causes of cancer death from gynecologic tumors in the world. Allopregnanolone (ALLO) is an active metabolite of progesterone (P4) involved in physiological and reproductive parameters of female rat. Previously we showed that ALLO affects on the hypothalamic-pituitary-gonadal axis in response to stress inducing mood disturbances and generating morphophysiological alterations in ovarian, being able to inhibit apoptosis and promote angiogenesis of corpora lutea. Furthermore, ALLO is able to inhibit ovulation and the formation of cystic structures. Epidemiological studies as well as in vitro assays have shown that P4 has anti-tumor effects. However, the molecular mechanism of the anticancer effect of progestogen had not yet fully understood. In addition, the effect of ALLO in ovarian cancer is unknown. Our hypothesis is that ALLO affects tumor progression. In this work, we analyzed the proliferation and migration of human ovarian cancer cells IGROV-1 and SKOV-3. To this end, both cell lines were exposed to different concentrations of ALLO (10-11-10-7 M) for 72 h and proliferation and migration were analyzed by MTS assay and wound assay respectively. We found that ALLO increased proliferation in a concentration dependent manner, reaching a maximum effect of 80% (p<0.001 vs. control: untreated cells). In SKOV-3 had an inhibitory effect on proliferation of 20% at 10-10 M ALLO (p <0.01 vs. control). Interestingly, ALLO increased the migration of cancer cells IGROV-1 in 60 % at 10-8 M (p<0.001 vs. control: untreated cells) and had the opposite effect in SKOV-3 cells, inhibiting by 25% the migration at 10-8 M (p <0.01 vs. control). We conclude that ALLO could modify proliferation and migration of ovarian cancer cells, affecting tumor progression. For this reason, we consider very important to continue elucidating the effect of this steroid in the biology of ovarian cancer.